Dr. Yan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Duke University Med Ctr
199 MSRB research dr
Durham, NC 27710- Is this information wrong?
Education & Training
- Beijing Medical UniversityClass of 1991
Publications & Presentations
PubMed
- 14 citationsNon-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe.Yang Liu, Austin B. Carpenter, Christopher J. Pirozzi, Hsiangkuo Yuan, Matthew S. Waitkus, Zhengyuan Zhou, Landon J. Hansen, Michelle Seywald, Ren Odion, Paula K. Gree...> ;Nanotechnology. 2019 Mar 11
- 3 citationsHereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency...Shahid Mahmood Baig, Ambrin Fatima, Muhammad Tariq, Tahir N. Khan, Zafar Ali, Mohammad Faheem, Humera Mahmood, Patrick J. Killela, Matthew S. Waitkus, Yiping He, Fangp...> ;Familial Cancer. 2019 Apr 1
- 107 citationsDetection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsyChunfeng Qu, Yuting Wang, Pei Wang, Kun Chen, Minjie Wang, Hongmei Zeng, Jianquan Lu, Qianqian Song, Bill H. Diplas, Tan Da, Chunsun Fan, Qigao Guo, Zheng Zhu, Huihui ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2019 Mar 26
- Join now to see all
Journal Articles
- The Genomic Landscape of TERT Promoter Wildtype-IDH Wildtype GlioblastomaDaniel B. Loriaux, Darel D. Bigner, Fausto J. Rodriguez, Hai Yan, Bil H. Diplas, Henry S. Friedman, Roger E. McLendon, Nature
Press Mentions
- REMD Biotherapeutics Announces Positive Top-Line Results in a Phase 2 Program of Lead Product Candidate Volagidemab in Patients with Type 1 DiabetesJune 28th, 2021
- REMD Biotherapeutics Completes Enrollment and Announces Top-Line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 DiabetesJanuary 7th, 2021
- Lessons in History, Hope and Living with Lynch Syndrome from the “Daughter of Family G”August 26th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: